Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model

Journal of Medicinal Food

Volumn 19, Issue 5, 2016, Pages 495-503

  Im, A Rang ^a   Kim, Yun Hee ^a   Lee, Hye Won ^a   Song, Kwang Hoon ^a,b  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

Author keywords

AMPK; Dolichos lablab; Free fatty acid; Nonalcoholic fatty liver disease

Indexed keywords

CD36 ANTIGEN; FAT DROPLET; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; LABLAB PURPUREUS EXTRACT; LIVER PROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLANT EXTRACT; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; CELL ENERGY; DRUG MECHANISM; GENE EXPRESSION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LABLAB PURPUREUS; LIPID LIVER LEVEL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; CHEMISTRY; DOLICHOS; DRUG EFFECTS; GENETICS; HEP-G2 CELL LINE; LIPID METABOLISM; LIVER; LIVER CELL; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHORYLATION;

AMP-ACTIVATED PROTEIN KINASES; DOLICHOS; FATTY ACIDS, NONESTERIFIED; HEP G2 CELLS; HEPATOCYTES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPID METABOLISM; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHORYLATION; PLANT EXTRACTS; PPAR GAMMA;

EID: 84969264298     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2015.3623     Document Type: Article

References (37)

1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
2. Mulhall BP, Ong JP, Younossi ZM: Non-alcoholic fatty liver disease: An overview. J Gastroenterol Hepatol 2002;17:1136-1143.
3. Lazo M, Clark JM: The epidemiology of nonalcoholic fatty liver disease: A global perspective. Semin Liver Dis 2008;28:339-350.
4. Zivkovic AM, German JB, Sanyal AJ: Comparative review of diets for the metabolic syndrome: Implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007;86:285-300.
5. Musso G, Gambino R, Cassader M: Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009;48:1-26.
6. Musso G, Gambino R, Cassader M: Non-alcoholic fatty liver disease from pathogenesis to management: An update. Obes Rev 2010;11:430-445.
7. Gaemers IC, Groen AK: New insights in the pathogenesis of nonalcoholic fatty liver disease. Curr Opin Lipidol 2006;17:268-273.
8. Malhi H, Gores GJ: Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28: 360-369.
9. McCullough AJ: Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40: S17-S29.
10. Li X, Wang R, Zhou N, et al.: Quercetin improves insulin resistance and hepatic lipid accumulation in a NAFLD cell model. Biomed Rep 2013;1:71-76.
11. Agbaga MP, Brush RS, Mandal MN, Henry K, Elliott MH, Anderson RE: Role of Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long chain fatty acids. Proc Natl Acad Sci USA 2008;105:12843-12848.
12. Kim MS, Kung S, Grewal T, Roufogalis BD: Methodologies for investigating natural medicines for the treatment of nonalcoholic fatty liver disease (NAFLD). Curr Pharm Biotechnol 2012;13: 278-291.
13. Yin J, Zhang H, Ye J: Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008;8:99-111.
14. Maheshu V, Priyadarsini DT, Sasikumar JM: Effects of processing conditions on the stability of polyphenolic contents and antioxidant capacity of Dolichos lablab L. J Food Sci Technol 2013;50:731-738.
15. Im AR, Chae SW, Zhang GJ, Lee MY: Neuroprotective effects of Psoralea corylifolia Linn seed extracts on mitochondrial dysfunction induced by 3-nitropropionic acid. BMC Complement Altern Med 2014;14:370.
16. Greenspan P, Fowler SD: Spectrofluorometric studies of the lipid probe, Nile red. J Lipid Res 1985;26:781-789.
17. McMillian MK, Grant ER, Zhong Z, et al.: Nile Red binDing to HepG2 cells: An improved assay for in vitro studies of hepatosteatosis. In Vitr Mol Toxicol 2001;14:177-190.
18. Song KH, Li T, Owsley E, Strom S, Chiang JY: Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7a-hydroxylase gene expression. Hepatology 2009;49:297-305.
19. Zhang C, Wang G, Zheng Z, et al.: Endoplasmic reticulumtethered transcription factor cAMP responsive element-binDing protein, hepatocyte specific, regulates hepatic lipogenesis, fatty acid oxidation, and lipolysis upon metabolic stress in mice. Hepatology 2012;55:1070-1082.
20. Xiao J, Fai SK, Liong EC, Tipoe GL: Recent advances in the herbal treatment of non-alcoholic Fatty liver disease. J Tradit Complement Med 2013;3:88-94.
21. Grefhorst A, Elzinga BM, Voshol PJ, et al.: Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002;277:34182-34190.
22. Repa JJ, Liang G, Ou J, et al.: Regulation of mouse sterol regulatory element-binDing protein-1c gene (SREBP-1c) by oxysterol receptors, LXRa and LXRb. Genes Dev 2000;14:2819-2830.
23. Zhou J, Febbraio M, Wada T, et al.: Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARc in promoting steatosis. Gastroenterology 2008;134:556-567.
24. Ducharme NA, Bickel PE: Lipid droplets in lipogenesis and lipolysis. Endocrinology 2008;149:942-949.
25. Greco D, Kotronen A, Westerbacka J, et al.: Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008; 294:G1281-G1287.
26. Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, et al.: Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 2008;60:311-357.
27. Fosslien E: Mitochondrial medicine-molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 2001;31:25-67.
28. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE: The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008;47:1495-1503.
29. Cortez-Pinto H, ChathamJ, Chacko VP, Arnold C, Rashid A, Diehl AM: Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study. JAMA 1999; 282:1659-1664.
30. Stankovic MN, Mladenovic D, Ninkovic M, et al.: The effects of a-lipoic acid on liver oxidative stress and free fatty acid composition in methionine-choline deficient diet-induced NAFLD. J Med Food 2014;17:254-261.
31. Srivastava S, Chan C: Hydrogen peroxide and hydroxyl radicals mediate palmitate-induced cytotoxicity to hepatoma cells: Relation to mitochondrial permeability transition. Free Radic Res 2007;41:38-49.
32. Gao D, Nong S, Huang X, et al.: The effects of palmitate on hepatic insulin resistance are mediated by NADPH oxidase 3-derived reactive oxygen species through JNK and p38MAPK pathways. J Biol Chem 2010;285: 29965-29973.
33. Mashek DG: Hepatic fatty acid trafficking: Multiple forks in the road. Adv Nutr 2013;4:697-710.
34. Yokota T, Baba J, Takahashi N: Brassinolide-related bioactive sterols in Dolichos lablab: Brassinolide, castasterone and a new analog, homodolicholide. Agric Biol Chem 1983;47:1409-1411.
35. Yokota T, Baba J, Koba S, Takahashi N: Purification and separation of eight steroidal plant-growth regulators from Dolichos lablab seed. Agric Biol Chem 1984;48:2529-2534.
36. Yoshiki Y, Kim JH, Okubo K, Nagoya I, Sakabe T, Tamura N: A saponin conjugated with 2,3-dihydro-2,5-dyhydroxy-6-methyl-4H-pyran-4-one from Dolichos lablab. Phytochemistry 1995;38: 229-231.
37. Kim YW, Lim SJ, Kim MA, Choi WC, Yoon HT: Determination and isolation of leaf isoflavone in hyacinth bean. Korean J Crop Sci 2001;46:449-452.